Market Intelligence, Clinical Progress, and High-Purity Reagents for p53-Targeted Oncology Development.
TarMart Solution Ecosystem & Related Targets
"Comprehensive reagent toolkit for MDMX (MDM4) drug discovery. Select your modality below:"
| Component / Network | Product Description | Product Link |
|---|---|---|
| Antigen | MDMX (MDM4) Recombinant Protein High purity (>95%), Endotoxin <1EU/ug. Sequence Verified. N-terminal p53-binding domain and full-length options. |
View MDM4 Products |
| Gene Delivery | MDMX (MDM4) Promise-ORF / Lentivirus Full-length ORF for stable cell line construction and overexpression validation. |
View MDM4 Products |
| Benchmark Ab | Anti-MDMX (MDM4) Recombinant Antibody Recombinant positive control for ELISA, Western Blot, and IP assays. |
View MDM4 Products |
| Validator | MDMX (MDM4) siRNA Set For target knockdown verification and specificity profiling. |
View MDM4 Products |
| Related Target A | MDM2 Primary heterodimerization partner of MDMX; critical for dual-inhibitor selectivity screening. |
View MDM2 Products |
| Related Target B | TP53 Direct downstream functional target; essential for validating p53 pathway reactivation. |
View TP53 Products |
| Critical Assay Challenge | The TarMart Advantage (Technical Spec) |
|---|---|
| Selectivity over MDM2 (homolog differentiation) | Human MDMX and MDM2 ortholog proteins strictly verified by mass spectrometry and SDS-PAGE to ensure precise assay baseline calibration. |
| Disruption of MDMX-p53 protein-protein interaction (PPI) | Conformational-integrity guaranteed recombinant MDMX p53-binding domain (1-185 aa) expressed with high purity (>95%). |
| Lack of Controls | Clinical benchmark antibodies (biosimilars) included for assay validation and comparative screening. |
| False Positives | Sequence-verified siRNA sets included for target-specific knockdown verification. |
Live MDMX (MDM4) R&D Tracker
Market data changes daily. Access the latest global pipeline status directly:
Global Clinical Landscape & Future Outlook
The therapeutic targeting of the p53 pathway is undergoing a significant renaissance. While early drug discovery focused heavily on MDM2 mono-inhibitors, clinical trials revealed that MDMX overexpression serves as a primary resistance mechanism, rendering MDM2 inhibition ineffective. Consequently, the industry is shifting rapidly toward dual MDM2/MDMX inhibitors, stapled peptides, and PROTAC-mediated degradation strategies to achieve robust p53 reactivation in wild-type p53 tumors.
Competitive Modality & Indication Snapshot
| Modality | Representative Players | Key Indications | Critical Assay Need (Why TarMart?) |
|---|---|---|---|
| Stapled Peptides | Aileron Therapeutics, ALRN-6924 | Solid Tumors, SCLC, Lymphoma | Competitive binding assays (Need high-purity MDMX and MDM2 to evaluate dual-affinity kinetics) |
| Small Molecule Inhibitors | Boehringer Ingelheim, Roche | Liposarcoma, AML, Glioblastoma | Selectivity profiling (Need high-purity recombinant MDMX vs MDM2 proteins) |
| PROTACs (Degraders) | Academic / Biotech Consortia | Breast Cancer, Melanoma | Target degradation kinetics (Need Lentivirus for stable cell line expression & Western verification) |